ALX Oncology Holdings (ALXO)
(Delayed Data from NSDQ)
$1.97 USD
+0.10 (5.35%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $1.96 -0.01 (-0.51%) 7:02 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
Brokerage Reports
0 items in cart
ALX Oncology Holdings Inc. [ALXO]
Reports for Purchase
Showing records 1 - 20 ( 32 total )
Company: ALX Oncology Holdings Inc.
Industry: Medical - Biomedical and Genetics
Data-Rich 2025 With Focus on ASPEN-03/04 Readout in 1H25; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: ALX Oncology Holdings Inc.
Industry: Medical - Biomedical and Genetics
ASPEN-06 Update is Suboptimal but De-risks Evorpacept; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: ALX Oncology Holdings Inc.
Industry: Medical - Biomedical and Genetics
Promising Data in EV-Naive Patients Reported
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: ALX Oncology Holdings Inc.
Industry: Medical - Biomedical and Genetics
Multiple Clinical Updates on the Horizon; New $25 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: ALX Oncology Holdings Inc.
Industry: Medical - Biomedical and Genetics
Potential of Evorpacept Combination Therapy in r/r B-NHL; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: ALX Oncology Holdings Inc.
Industry: Medical - Biomedical and Genetics
Catalyst-Rich 2024; New $20 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: ALX Oncology Holdings Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for ALXO 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: ALX Oncology Holdings Inc.
Industry: Medical - Biomedical and Genetics
Company: ALX Oncology Holdings Inc.
Industry: Medical - Biomedical and Genetics
Evorpacept Shines in Gastric Cancers; New PT $17.50; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: ALX Oncology Holdings Inc.
Industry: Medical - Biomedical and Genetics
MDS and AML Programs Shelved; Lower PT to $16; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: ALX Oncology Holdings Inc.
Industry: Medical - Biomedical and Genetics
Focus Remains on ASPEN-02 and ASPEN-06 Updates in 2H23; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: ALX Oncology Holdings Inc.
Industry: Medical - Biomedical and Genetics
Eyes on Upcoming MDS Data From ASPEN-02 Study; PT Lowered To $30; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: ALX Oncology Holdings Inc.
Industry: Medical - Biomedical and Genetics
Key Takeaways From Our Fireside Chat with Dr. Michael Bishop on AML
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: ALX Oncology Holdings Inc.
Industry: Medical - Biomedical and Genetics
ASPEN-05 Data Update Highlights Evorpacept?s Potential in Newly Diagnosed AML; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: ALX Oncology Holdings Inc.
Industry: Medical - Biomedical and Genetics
Promising Phase 1 Data of ASPEN-05 at ASH; Adusting PT to $65; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: ALX Oncology Holdings Inc.
Industry: Medical - Biomedical and Genetics
Expanding Solid Tumor Indications; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S